Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
178
datasets available to search
ShareScore release 0.9.0
Dataset results
178 results for “Clinical progression”
Genome-wide determinants of mortality and clinical progression in Parkinson's disease - Summary statistics
<p>Summary statistics from "Genome-wide determinants of mortality and clinical progression in Parkinson’s disease".</p>
A more accurate risk biomarkers recognition for Progressive Multifocal Leukoencephalopathy (PML) caused by Polyomavirus JC in patients with multiple sclerosis during treatment with disease-modifying therapies (DMTs): an ongoing clinical challenge.
<p>The therapeutic scenario for the treatment of MS has recently been characterized by a veritable revolution, which has included the introduction, for the first time, of drug treatment guidelines and the entry, in the therapeutic landscape of the last decade, of numerous new drugs that, in varying but significantly relevant ways, have proven capable of modifying the course of the disease (Disease-Modifying Therapies - DMTs). <br> While the arsenal of available drugs has resulted in advances in efficacy and selectivity, it has also exposed them to the danger of side effects, potentially serious and in some cases even fatal. Among the most important side effects, complications of infectious origin, characterized by cases of viral infection/reactivation, as in the case of JCPyV, the etiologic agent of PML, are the most represented. This study, based on the follow-up of MS patients treated with different DMTs, contributes to implementing the data in the literature regarding a greater understanding of the risks related to the administration of these drugs and more appropriate monitoring of MS treatment. The risk of JCPyV reactivation with Fingolimod and Dimethyl fumarate is lower than the risk of viral reactivation associated with natalizumab.<br> In light of the data obtained, it is possible to conclude that, in the case of natalizumab, testing for JC viruria would seem to be more useful in identifying those patients with a JCPyV-specific humoral response that is not yet detectable. In addition, our results, draw attention to the importance of analyzing the NCCR rearrangements of JCPyV. Indeed, the particular rearrangements found in plasma and PBMCs of patients with RRMS treated with natalizumab could represent an alert of neuroinvasiveness in order to detect early those patients with a higher risk of developing PML. In the case of dimethyl fumarate, it seems likely that monitoring of lymphopenia would identify a higher risk group of patients in whom alternative therapy should be sought. Prolonged lymphopenia, with absolute lymphocyte counts less than 750 lymphocytes/mL, might be the major risk factor for PML although, a greater risk might lie in the loss of CD8+ cells that are crucial for JCPyV control.<br> For fingolimod, this strategy cannot be applied because the number of circulating lymphocytes decreases while the actual lymphocyte function appears largely normal therefore, monitoring viruria and viremia along with identification of the neurotrophic variant of the virus seems a more exploitable means for risk stratification.</p> <p>In conclusion, the results of this study can be considered directly transferable to the National Health System in that, both the monitoring of JCPyV reactivation by viruria and the sequence analysis of viral NCCR and host immune set-up could play the role of translatable biomarkers in clinical practice in order to assess the risk of PML onset. In addition to improving risk stratification of this disease, these biomarkers of viral reactivation and pathogenicity could facilitate timely diagnosis, optimizing the use of health care resources and contributing to the reduction of direct and indirect costs of MS disease.</p> <p>Prezioso Carla was supported by the Italian Ministry of Health (Starting Grant: SG-2018-12366194).</p>
Clinical Trial of Safety and Efficacy of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression
ClinicalTrials.gov study NCT01716104. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Clinical Assessment of a Customized Free-form Progressive Addition Lens Spectacle
ClinicalTrials.gov study NCT01234207. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease
ClinicalTrials.gov study NCT03011775. IPD Sharing: NO. Countries: 1. Publications: 1.
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
ClinicalTrials.gov study NCT00950248. IPD Sharing: YES. Countries: 1. Publications: 5.
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
ClinicalTrials.gov study NCT01416181. IPD Sharing: Not stated. Countries: 17. Publications: 4.
Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
ClinicalTrials.gov study NCT02193867. IPD Sharing: Not stated. Countries: 4. Publications: 3.
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatme
ClinicalTrials.gov study NCT02156804. IPD Sharing: Not stated. Countries: 20. Publications: 2.
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Expe
ClinicalTrials.gov study NCT02284568. IPD Sharing: Not stated. Countries: 10. Publications: 2.
Advanced 4-chamber echocardiography techniques enable clinically matched precise characterization of heart disease progression in mice
Open the record for dataset details and reuse information.
ATN-classification and clinical progression in subjective cognitive decline: the SCIENCe project
<p>Objective: To investigate the relationship between the ATN-model and risk of dementia and cognitive decline in individuals with subjective cognitive decline (SCD).</p> <p>Methods: We classified 693 participants with SCD (60±9yr, 41%F, MMSE 28±2) from the Amsterdam Dementia Cohort and SCIENCe project according to the ATN-model, as determined by amyloid PET or CSF Abeta (A), CSF p-tau (T) and MRI-based medial temporal lobe atrophy (N). All underwent extensive neuropsychological assessment. For 342 participants follow-up was available (3±2yr). As a control population, we included 124 participants without SCD.</p> <p>Results: 56% (n=385) participants had <i>normal AD biomarkers </i>(A-T-N-), 27% (n=186) had <i>non-AD pathologic change</i> (A-T-N+, A-T+N-, A-T+N+), 18% (n=122) fell within the <i>Alzheimer's continuum </i>(A+T-N-, A+T-N+, A+T+N-, A+T+N+). ATN profiles were unevenly distributed, with A-T+N+, A+T-N+ and A+T+N+ containing very few participants. Cox regression showed that compared to A-T-N-, participants in A+ profiles had a higher risk of dementia with a dose-response pattern for number of biomarkers affected. Linear mixed models showed participants in A+ profiles showed a steeper decline on tests addressing memory, attention, language, and executive functions. In the control group, there was no association between ATN and cognition.</p> <p>Conclusions: Among individuals presenting with SCD at a memory clinic, those with a biomarker profile A-T+N+, A+T-N-, A+T+N- and A+T+N+ were at increased risk of dementia, and showed steeper cognitive decline compared to A-T-N- individuals. These results suggest a future where biomarker results could be used for individualized risk profiling in cognitively normal individuals presenting at a memory clinic.</p>
Association of gray matter atrophy patterns with clinical phenotype and progression in multiple sclerosis
<p><b>Objectives.</b> Grey matter (GM) involvement is clinically relevant in multiple sclerosis (MS). Using source-based morphometry (SBM), we characterized GM atrophy and its 1-year evolution across different MS phenotypes.</p> <p><b>Methods.</b> Clinical and MRI data were obtained at 8 European sites from 170 healthy controls (HCs) and 398 MS patients (34 clinically isolated syndromes [CIS], 226 relapsing-remitting [RR], 95 secondary progressive [SP] and 43 primary progressive [PP] MS). Fifty-seven HC and 144 MS underwent 1-year follow-up. Baseline GM loss, atrophy progression and correlations with disability and 1-year clinical worsening were assessed.</p> <p><b>Results.</b> SBM identified 26 cerebellar, subcortical, sensory, motor and cognitive GM components. GM atrophy was found in MS <i>vs</i> HC in almost all components (p=range<0.001-0.04). Compared to HCs, CIS patients showed circumscribed subcortical, cerebellar, temporal and salience GM atrophy, while RRMS patients exhibited widespread GM atrophy. Cerebellar, subcortical, sensorimotor, salience and fronto-parietal GM atrophy was found in PPMS patients <i>vs</i> HCs, and SPMS <i>vs</i> RRMS. At 1-year, 21 (15%) patients had clinically worsened. GM atrophy progressed in MS in subcortical, cerebellar, sensorimotor, and fronto-temporo-parietal components. Baseline higher disability was associated (R<sup>2</sup>=0.65) with baseline lower normalized brain volume (beta=-0.13, p=0.001), greater sensorimotor GM atrophy (beta=-0.12, p=0.002) and longer disease duration (beta=0.09, p=0.04). Baseline normalized GM volume (odds ratio=0.98, p=0.008) and cerebellar GM atrophy (odds ratio=0.40, p=0.01) independently predicted clinical worsening (area-under-the-curve=0.83).</p> <p><b>Conclusion. </b>GM atrophy differed across disease phenotypes and progressed at 1-year in MS. In addition to global atrophy measures, sensorimotor and cerebellar GM atrophy explained baseline disability and clinical worsening.</p>
Effects of the Hypnotic Alkylphenol Derivative Propofol on Breast Cancer Progression. A Focus on Preclinical and Clinical Studies.
<p>Propofol is a hypnotic alkylphenol derivative with many biological activities. It is predominantly used in anesthesia and is the most used parenteral anesthetic agent in the United States. Accumulating preclinical studies have shown that this compound may inhibit cancer recurrence and metastasis. Nevertheless, other investigations provided evidence that this compound may promote breast cancer cell progression by modulating different molecular pathways. Clinical data on this topic are scarce and derive from retrospective analyses. For this reason, we reviewed and evaluated the available data to reveal insight into this controversial issue. More preclinical and clinical investigations are necessary to determine the potential role of propofol in the proliferation of breast cancer cells.</p>
Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression (CSL)
ClinicalTrials.gov study NCT05724186. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Role of Renal Resistive Index (RI) in Predicting Acute Kidney Injury Progression in Intensive Care Clinic
ClinicalTrials.gov study NCT06995222. IPD Sharing: YES. Countries: 1. Publications: 1.
Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression
ClinicalTrials.gov study NCT00134784. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Clinical and Laboratory Factors for the Progression of Severe Dengue Among Hospitalized Patients During an Upsurge
ClinicalTrials.gov study NCT06697041. IPD Sharing: NO. Countries: 1. Publications: 8.
STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk
ClinicalTrials.gov study NCT01442896. IPD Sharing: Not stated. Countries: 1. Publications: 4.
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
ClinicalTrials.gov study NCT04889872. IPD Sharing: NO. Countries: 6. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.